Abstract:Major depressive disorder (MDD) is a recurrent episodic mood disorder that represents the third leading cause of disability worldwide. In MDD, several factors can simultaneously contribute to its development, which complicates its diagnosis. According to practical guidelines, antidepressants are the first-line treatment for moderate to severe major depressive episodes. Traditional treatment strategies often follow a one-size-fits-all approach, resulting in suboptimal outcomes for many patients who fail to experience a response or recovery and develop the so-called "therapy-resistant depression". The high biological and clinical inter-variability within patients and the lack of robust biomarkers hinder the finding of specific therapeutic targets, contributing to the high treatment failure rates. In this frame, precision medicine, a paradigm that tailors medical interventions to individual characteristics, would help allocate the most adequate and effective treatment for each patient while minimizing its side effects. In particular, multi-omic studies may unveil the intricate interplays between genetic predispositions and exposure to environmental factors through the study of epigenomics, transcriptomics, proteomics, metabolomics, gut microbiomics, and immunomics. The integration of the flow of multi-omic information into molecular pathways may produce better outcomes than the current psychopharmacological approach, which targets singular molecular factors mainly related to the monoamine systems, disregarding the complex network of our organism. The concept of system biomedicine involves the integration and analysis of enormous datasets generated with different technologies, creating a "patient fingerprint", which defines the underlying biological mechanisms of every patient. This review, centered on precision medicine, explores the integration of multi-omic approaches as clinical tools for prediction in MDD at a single-patient level. It investigates how combining the existing technologies used for diagnostic, stratification, prognostic, and treatment-response biomarkers discovery with artificial intelligence can improve the assessment and treatment of MDD.

From Early Diagnosis to Emerging Treatment Options

Depression, mitochondrial bioenergetics, and electroconvulsive therapy: a new approach towards personalized medicine in psychiatric treatment - a short review and current perspective

Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges

Insights into Major Depression as a Mitochondria-Associated Disease

New and emerging treatments for major depressive disorder

Mitochondrial Dysfunction as a Biomarker of Illness State in Bipolar Disorder: A Critical Review

Mitochondrial Dysfunction in the Pathophysiology of Bipolar Disorder: Effects of Pharmacotherapy

Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications

Gut Microbiota Metabolites in Major Depressive Disorder—Deep Insights into Their Pathophysiological Role and Potential Translational Applications

Molecular, Functional, and Structural Imaging of Major Depressive Disorder

Mitochondria in depression: The dysfunction of mitochondrial energy metabolism and quality control systems

Emerging drugs for the treatment of major depressive disorder

Major Depressive Disorder and Oxidative Stress: A Review of Peripheral and Genetic Biomarkers According to Clinical Characteristics and Disease Stages

A new approach for the treatment of subthreshold bipolar disorders: Targeted high dose levothyroxine and repetitive transcranial magnetic stimulation for mitochondrial treatment

Targeting Gap Junctions: New Insights into the Treatment of Major Depressive Disorder

Mitochondrial dysfunction: A fatal blow in depression

Potential Anti-Depressive Treatment Maneuvers from Bench to Bedside.

Omics approaches open new horizons in major depressive disorder: from biomarkers to precision medicine

Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes

Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression

Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology